MedPath

Phase 2 study of Nab-Paclitaxel for patients with previously treated EGFR wild-type non-small-cell lung cancer.

Phase 2
Conditions
on-small-cell lung cancer
Registration Number
JPRN-UMIN000018233
Lead Sponsor
Shimane university hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
45
Inclusion Criteria

Not provided

Exclusion Criteria

1)Brain metastasis with the symptom 2)Active interstitial pneumonia or pulmonary fibrosis 3)Body fluid retention to need waste fluid 4)Hypersensitivity for paclitaxel or albumin 5)Pregnant or nursing female or man without the intention of the contraception 6)Active concomitant malignancy 7)Inappropriate patients for this study judged by the physicians

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath